These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. When, why and how to order blood? Steenssens L Acta Anaesthesiol Belg; 2003; 54(4):313-4. PubMed ID: 14719351 [No Abstract] [Full Text] [Related]
43. [Platelet and granulocyte transfusion in hematology]. Ouellet P Union Med Can; 1983 May; 112(5):457-60. PubMed ID: 6879858 [No Abstract] [Full Text] [Related]
45. Blood transfusion reactions. Shafer N; Wilkenfeld M; Shafer R Leg Med; 1980; ():207-20. PubMed ID: 7421388 [TBL] [Abstract][Full Text] [Related]
46. [Blood group determination and blood transfusion]. Mueller-Eckhardt C Dtsch Med Wochenschr; 1991 Jan; 116(3):116. PubMed ID: 1986910 [No Abstract] [Full Text] [Related]
47. [Evaluation of the guideline for a good practice of transfusion therapy]. Nakajima H Rinsho Byori; 1991 Mar; Suppl 88():305-12. PubMed ID: 1856984 [No Abstract] [Full Text] [Related]
49. [Transfusional record and blood grouping methods: essential factors of transfusion safety]. Clavier B; Trueba F; Bertin B; Descraques C; Hernandez E; Joussemet M Transfus Clin Biol; 2002 Oct; 9(4):265-7. PubMed ID: 12469558 [TBL] [Abstract][Full Text] [Related]
50. [Identification strategy of RHCE gene variants at the National Blood Group Reference Laboratory: impact on transfusion safety]. Ansart-Pirenne H Transfus Clin Biol; 2006; 13(1-2):13-8. PubMed ID: 16563835 [TBL] [Abstract][Full Text] [Related]
52. [Protection against mismatched transfusion during operation double check system]. Yasukawa K; Yasukawa M; Niibuchi K; Homma Y Masui; 2005 Nov; 54(11):1315-8. PubMed ID: 16296380 [TBL] [Abstract][Full Text] [Related]
53. Hemolysis from ABO Incompatibility. Simmons DP; Savage WJ Hematol Oncol Clin North Am; 2015 Jun; 29(3):429-43. PubMed ID: 26043383 [TBL] [Abstract][Full Text] [Related]
54. Brush up your medicine: blood transfusion. Isbister JP Med J Aust; 1980 May; 1(9):411-3. PubMed ID: 7393092 [No Abstract] [Full Text] [Related]
55. The clinical significance of blood group antibodies. Daniels G; Poole J; de Silva M; Callaghan T; MacLennan S; Smith N Transfus Med; 2002 Oct; 12(5):287-95. PubMed ID: 12383334 [No Abstract] [Full Text] [Related]
56. [Blood and blood product transfusions. Immunological basis and indications]. Andreu G Rev Prat; 2001 Feb; 51(3):299-305. PubMed ID: 11265428 [No Abstract] [Full Text] [Related]
57. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Denomme GA; Wagner FF; Fernandes BJ; Li W; Flegel WA Transfusion; 2005 Oct; 45(10):1554-60. PubMed ID: 16181204 [TBL] [Abstract][Full Text] [Related]
58. A new paradigm for pretransfusion testing with the same perennial limitations. Westhoff CM; Anstee DJ Transfusion; 2010 Mar; 50(3):520-1. PubMed ID: 20609198 [No Abstract] [Full Text] [Related]
59. Patients with red cell autoantibodies: selection of blood for transfusion. Sokol RJ; Hewitt S; Booker DJ; Morris BM Clin Lab Haematol; 1988; 10(3):257-64. PubMed ID: 3180694 [TBL] [Abstract][Full Text] [Related]
60. [Preventive measures against transfusion-associated complications and side effects]. Suzuki M; Ikebuchi K Masui; 2008 Sep; 57(9):1075-86. PubMed ID: 18807893 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]